Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AngioJet Thrombectomy System Aids Cost Saving In DES Procedures – Possis

This article was originally published in The Gray Sheet

Executive Summary

The advent of drug-eluting stents (DES) is benefiting sales of Possis Medical's AngioJet Rheolytic thrombectomy system, the firm says

You may also be interested in...



Possis RX Heart Catheter Approval, Anticipation Of AiMI Data Boost Stock

Possis Medical's receipt of PMA supplement approval for coronary use of its AngioJet Rheolytic XMI-RX rapid exchange thrombectomy catheter helped propel the firm's stock ahead 12% in May to $28.49

Possis RX Heart Catheter Approval, Anticipation Of AiMI Data Boost Stock

Possis Medical's receipt of PMA supplement approval for coronary use of its AngioJet Rheolytic XMI-RX rapid exchange thrombectomy catheter helped propel the firm's stock ahead 12% in May to $28.49

Possis Medical AngioJet XMI-RX

Rapid-exchange version of the firm's XMI Rheolytic thrombectomy catheter is approved via PMA supplement for coronary use with the firm's AngioJet system. Previously approved for peripheral use, XMI-RX also has received a CE mark for coronary use in Europe, clearing the way for its launch at the Paris Course on Revascularization meeting May 25-28. The firm expects the catheter to boost AngioJet market penetration (1"The Gray Sheet" Feb. 23, 2004, p. 21)...

Related Content

UsernamePublicRestriction

Register

MT019774

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel